Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by bull8888on Feb 26, 2006 7:21pm

275 Views

Post# 10427277

PDF Copy of Webcast

Here is the contact info if you want a PDF copy of the webcast. This is taken from the RVX website: WebCast - February 23, 2006 Resverlogix Corp. held a webcast on February 23, 2006 to allow securities analysts, shareholders and other key stakeholders the opportunity to hear management discuss the company's strategic objectives for 2006 and corporate updates in regards to its ongoing licensing negotiations for its ReVas™ program. To obtain a PDF version of this WebCast, please contact: Kenneth Lebioda VP Business & Market Development 403.254.9252

Bullboard Posts

Victory Battery Metals acquires Utah and Saskatchewan uranium projects